Actalent is currently hiring for a Histotechnologist opportunity in the Washington D.C location!

　　Job Description:

　　ASCP certified clinical laboratory scientist or histotechnologist with at least one year of IHC experience. Experience performing antibody validations would be optimal. IHC experience must be using DAKO automation and/or technologist must have HQIP examination certification.

　　Technologist must be flexible and willing to perform other duties in the anatomic pathology laboratory as staffing needs including the following:

　　Slide distribution.

　　Accessioning

　　Slide and block filing.

　　Embedding & microtomy

　　Tissue processor changing

　　Cytology FNA coverage

　　Cytology medical sample preparation

　　Skills:

　　Staining, Pathology, IHC, ASCP, Laboratory, Biology, Chemistry, Accessioning, Tissue samples

　　Additional Skills & Qualifications:

　　ASCP OR AMT Certification

　　Histotechnologist specific skills including: embedding, microtomy , and IHC.

　　IHC experience is a must

　　Diversity, Equity & Inclusion

　　At Actalent, diversity and inclusion are a bridge towards the equity and success of our people. DE&I are embedded into our culture through:

　　Hiring diverse talent

　　Maintaining an inclusive environment through persistent self-reflection

　　Building a culture of care, engagement, and recognition with clear outcomes

　　Ensuring growth opportunities for our people

　　Actalent is an equal opportunity employer.

　　About Actalent

　　Actalent connects passion with purpose. We help visionary companies advance their engineering and science initiatives through access to specialized experts that drive scale, innovation, and speed to market. With a network of almost 30,000 engineering and sciences consultants and more than 4,500 clients across the U.S., Canada, Asia, and Europe, Actalent serves many of the Fortune 500. An operating company of Allegis Group, the global leader in talent solutions, Actalent launched as a new specialized engineering and sciences services and workforce solutions brand in 2021.